DJ MARKET TALK: Goldman Sachs Lifts Genmab Target

09/21/06 - Dow Jones Newswires

0928 GMT [Dow Jones] Goldman Sachs ups Genmab (GEN.KO) target to DKK324 from DKK271, citing the increased probability of success in the HuMax-CD20 program. Says new model includes potential upfront milestone payments from a partnering deal for HuMax-CD20, which could occur much sooner than the expected mid-07. Lifts 09 revenue and profit forecasts, based on the launch of HuMax-CD20 for Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia. Keeps at buy. Shares +2.2% at DKK228. (MKR)

 
Contact us in London. +44-20-7842-9464 
Markettalk.eu@dowjones.com 
 
 

(END) Dow Jones Newswires

September 21, 2006 05:28 ET (09:28 GMT)

Copyright (c) 2006 Dow Jones & Company, Inc.